Contract notice
Section I: Contracting
authority
I.1) Name and addresses
Medicines Discovery Catapult
Block 35, Mereside, Alderley Park
Cheshire
SK10 4ZF
UK
Contact person: James Tomlinson
Telephone: +44 1625708394
E-mail: james.tomlinson@md.catapult.org.uk
NUTS: UK
Internet address(es)
Main address: https://md.catapult.org.uk/
Address of the buyer profile: https://md.catapult.org.uk/
I.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge at:
https://procontract.due-north.com/RFx/RFxSummary?rfxId=532e9bbc-1846-ed11-811a-005056b64545&projectId=482d48e6-1046-ed11-811a-005056b64545
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be sent electronically to:
https://procontract.due-north.com/RFx/RFxSummary?rfxId=532e9bbc-1846-ed11-811a-005056b64545&projectId=482d48e6-1046-ed11-811a-005056b64545
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Other: Drug Discovery / Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Electronic Quality Management System (eQMS) for Medicines Discovery Catapult
Reference number: DN636698
II.1.2) Main CPV code
72000000
II.1.3) Type of contract
Services
II.1.4) Short description
Medicines Discovery Catapult (MDC) is a national facility for collaborative R&D exploring and developing new approaches to the discovery and proof of well targeted medicines, diagnostics and biomarkers. Funded by Innovate UK, an agency of the UK government, MDC are an independent not-for-profit company bringing together a fragmented UK sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high value products. By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change.
MDC requires a robust Electronic Quality Management System (eQMS) to support business growth and new projects involving clinical samples. The new eQMS is required to provide full traceability for all activities pertaining to clinical samples, whilst also supporting MDC’s operations at large.
Further information can be found at https://procontract.due-north.com/RFx/RFxSummary?rfxId=532e9bbc-1846-ed11-811a-005056b64545&projectId=482d48e6-1046-ed11-811a-005056b64545
II.1.5) Estimated total value
Value excluding VAT:
455 000.00
GBP
II.1.6) Information about lots
This contract is divided into lots:
No
II.2) Description
II.2.3) Place of performance
NUTS code:
UK
II.2.4) Description of the procurement
Medicines Discovery Catapult (MDC) is a national facility for collaborative R&D exploring and developing new approaches to the discovery and proof of well targeted medicines, diagnostics and biomarkers. Funded by Innovate UK, an agency of the UK government, MDC are an independent not-for-profit company bringing together a fragmented UK sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high value products. By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change.
MDC requires a robust eQMS to support business growth and new projects involving clinical samples. The new eQMS is required to provide full traceability for all activities pertaining to clinical samples, whilst also supporting MDC’s operations at large.
An open procurement procedure is being used.
Further information can be found at https://procontract.due-north.com/RFx/RFxSummary?rfxId=532e9bbc-1846-ed11-811a-005056b64545&projectId=482d48e6-1046-ed11-811a-005056b64545
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/01/2023
End:
31/12/2030
This contract is subject to renewal: Yes
Description of renewals:
This is an initial 3-year contract, with the option to extend for a further four separate 1-year periods subject to the awarded suppliers satisfactory performance.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.2) Time limit for receipt of tenders or requests to participate
Date:
07/11/2022
Local time: 15:00
IV.2.4) Languages in which tenders or requests to participate may be submitted
EN
IV.2.7) Conditions for opening of tenders
Date:
07/11/2022
Local time: 15:00
Section VI: Complementary information
VI.1) Information about recurrence
This is a recurrent procurement:
No
VI.4) Procedures for review
VI.4.1) Review body
Medicines Discovery Catapult
Block 35, Mereside, Alderley Park,
Cheshire
UK
VI.5) Date of dispatch of this notice
07/10/2022